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Chapter 1. SARS-CoV-2 and the nervous 
system: review on pathogenesis of  nervous 
system SARS-CoV-2 damage
 
Coronaviridae family, belonging to the genus of  all highly pathogenic coronavi-
ruses, i.e., Betacoronavirus1 -
-
China in 20022 3
Hubei province of  China in 2019 most likely due to species barrier spillover, 




encodes for accessory and structural proteins4,5,9; the latter include spike (S), 
envelope (E), membrane (M), and nucleocapsid (N) proteins. The S protein is 
and the other the membrane fusion domain, i.e., S1 and S2, respectively. The 
binding is followed by proteolytic activation between S1/S2 at the plasma mem-
membrane by cathepsin L10. The genome is then released in the cytosol where it 
in accessory and structural proteins used for virion assembly. Finally, the viral 
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plasma membrane9,11,12
having entered the host via epithelial cells, the vascular endothelial cells and 
13-15.
. Severe 
and the factors that dictate whether or not a patient develops the severe form 
are not yet known, although older age is one of  the main known risk factors 
associated with severity together with obesity, cardiovascular diseases and male 
17-19, 
immune activation. The increased cytokine and chemokine concentration 
20. 
-
toms17,21,22, which roughly corresponds to the temporal bridging of  the innate 
and adaptive immune response. Once the disease becomes systemic, the disease 
will involve other organs and systems. 
SARS-CoV-2 and the nervous system: pathogenetic aspects
Central nervous system and peripheral nervous system manifestations in 
COVID-19 disease
Central nervous system (CNS) and peripheral nervous system (PNS) involve-
a small proportion of  cases: in fact, the prevalence of  CNS and PNS compli-
23. As the COVID-19 pandemic 
progressed, neurological manifestations increased. These included neurological 
symptoms that are present at the time of  COVID-19 diagnosis in a considerable 
number of  patients, and neurological complications that could appear later . 
The neurological manifestations in COVID-19 disease have been catego-
rized in three groups: (i) CNS involvement, characterized by dizziness, head-
ache, impaired consciousness, acute cerebrovascular disease and epilepsy; (ii) 
PNS involvement, including anosmia, hypogeusia, visual impairment and neu-
ralgia; and (iii) skeletal muscle impairment27. Neurological symptoms, such as 
loss of  the sense of  smell and taste, headache, fatigue, nausea and vomiting, 
dizziness, are reported in more than one-third of  COVID-19 patients17,28; but 
more severe manifestations, as well as encephalopathy, stroke, Guillain-Barré 
syndrome, acute hemorrhagic necrotizing encephalitis, and acute disseminated 
31. SARS-CoV-2 and the nervous system
encephalomyelitis seem to be less common23,29. However, the prevalence of  
neurological manifestations associated with COVID-19 varies widely among 
the different studies, ranging from 7% to over 84%27,30.
Given the high prevalence of  COVID-19 disease worldwide, and the 
-
tion, that are, in fact, described also in the course of  other viral infections, 
CoV-2 and neurological symptoms27. The pathogenesis of  CNS infection by 
and more pathogenetic studies are needed to shed light on this topic.
ACE2 receptors are expressed in different brain regions
-
and in several cell types, such as neurons and glia ; recently, ACE2 has also 
been found in the human cerebral vasculature in postmortem brain samples 
-
sion31,32. ACE2 in brain was also found in the neurons of  the subfornical organ, 
the lack of  a blood brain barrier (BBB)7. Additional receptors may play a role in 
its protease in host has been demonstrated to be critical for the neurotropism 
of  the Coronaviridae
33.
Possible mechanisms of  neurotropism and neurovirulence of  SARS-CoV-2
direct or indirect mechanism. The possible mechanisms of  neurological im-
entry into the CNS; (ii) para-infectious or post-infectious immune-mediated 
disease; (iii) a secondary involvement of  the CNS following the systemic effects 
multiorgan failure23,24
three phases: (i) neuroinvasion; (ii) CNS clearance; and (iii) immune response. 
and/or through the trans-cribriform route along the olfactory nerve; it seems 
that the viral load in the CSF gradually increases until the second phase. In the 
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second phase, the interaction between the subunit S1 of  the spike protein and 
the ACE2 receptor allows viral entry into the neuronal cells with subsequent 
neuronal damage; early after the infection, neuronal damage leads to the onset 
of  anosmia and/or dysgeusia, while later the involvement of  the nucleus of  
the solitary tract may cause severe respiratory impairment. During the second 
CNS. In the third and last phases, the viral infection causes immune-mediat-
ed CNS impairment. The virus could stimulate the production of  antibodies 
against glial cells, as a para- or post-infective mechanism, similar to that ob-
served after other viral infections. In this phase, the respiratory symptoms may 
34.
CNS impairment as a consequence of  a direct viral effect 
-
organoids
replicate in induced pluripotent stem cell (iPSCs)-derived human neural progen-
itor cells (hNPCs) and in neurospheres or brain organoids produced from these 
cells25,32
-
ferent brain areas, and this was later compared with the pulmonary involvement. 
Interestingly, not all infected animals showed neurological symptoms or signs of  
CNS infection24
, even if  with a low frequency.





could be that the virus is cell-bound and spreads from cell to cell and does not 
transit freely in the CSF. Alternatively, the viral concentrations in the CSF could 
the presence of  hemoglobin products for the breakdown of  erythrocytes. The 
detection rate is also highly dependent on the type of  neurological disease and 
the time of  sample collection41. Finally, the absence of  the virus in the CSF 
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protein levels described in some patients with encephalitis) suggests that the 
. 
patients diagnosed with encephalitis and much lower in patients with encephalop-
athy, cerebrovascular accidents or Guillain-Barré syndrome. Interestingly, patients 
41. 
-
cording to available data, 23.3% of  tested patients present intrathecal antibody syn-
thesis41 that could suggest the invasion of  the virus into the CNS47.
Detection of  SARS-CoV-2 in brain tissue samples
-
sion, in addition to that of  the CSF, and previous studies have investigated the 
contrasting results. Some authors, in fact, reported the detection of  the virus in 
-
chemistry . Conversely, in other studies, the virus was not detected in brain 
cells. Thus, the hypothesis that the virus is intrinsically neuroinvasive and is able to 
27,49,50
was detected in different cell types as well as frontal lobe neurons, glial cells, en-
45,51-53, and viral 
proteins were found in a smaller proportion of  patients in different brain regions, 
as well as brainstem, cerebellum, cerebrum and the olfactory system41. The high-
-
41.
41 and microglial activation was found 
in the compromised brain areas in more than half  the patients. The detection 
41.
Routes of  neuroinvasion
Coronaviruses may reach the CNS through any of  three different path-
(iii) neuronal retrograde propagation27,28,54,55
viremia, the virus can cross the BBB and enter the CNS.
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Figure 1.1: Possible SARS-CoV-2 entry to the central nervous system (CNS)  
via blood circulation
cells to the blood circulation; crossing of  the Blood Brain Barrier (BBB) and inva-
25 with permission.
The passage of  the virus to the blood circulation may follow the infection 
53. The most plausible scenario is that of  access through 
infection, including endothelial necrosis and capillary injury, has been demon-
strated in postmortem analyses, and suggests that the virus can translocate from 
the lungs to the pulmonary microcirculation and then spread to other organs .
-
cytes and monocytes, and the latter, activated by the infection, can disseminate and 
cross the BBB; infected macrophages have been described in COVID-19, suggest-
. Finally, the 
-
teins called dinein and kinesin, both possible targets of  the virus57,58. 
The virus can either infect endothelial cells of  the BBB or epithelial cells of  
71. SARS-CoV-2 and the nervous system
Figure 1.2: Passage of  SARS-CoV-2 through the Blood Brain Barrier triggering 
a)
b)
the integrity of  the Blood Brain Barrier (BBB) and allow the entry of  other viruses 
-
  with permission.
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During transcellular migration, the virus invades host endothelial cells to 
cross the BBB, while during paracellular migration, the virus invades the tight 
junctions formed by the endothelial cells59
in human brain microvascular endothelial cells (BMVECs) and may allow viral 
-
sion electron microscopy has found the presence of  viral-like proteins inside 
BMVECs in the frontal lobe45
thanks to its greater permeability compared to BBB, it could provide a second 
entry route to the CNS ; on the other hand, the low viral load in the blood 
makes this an unlikely means of  entry to the CSN25.
BBB is negatively affected by viral infections, not only thanks to the pro-
ductive or non-productive infection of  endothelial cells, but also by the host 
-
tural and functional integrity of  the BBB31
break down the BBB by reducing the integrity of  the tight junction proteins . 
In turn, BBB dysfunction creates a vicious circle, allowing the passage of  other 
free viral particles and infected immune cells to the CNS.
The increase in BBB permeability has been described in COVID-19 patients 
with neurological symptoms
CoV-2 in modifying BBB properties has been reported. In a BBB-on-a-chip 
in vitro
-




Furthermore, the virus or infected lymphocytes could stimulate the production 
as CCL5, CXCL10 and CXCL11, that can induce chemoattraction of  other acti-
vated T cells in the CNS. Activated astrocytes can, in turn, produce chemokines 




ing the fact that the virus can hide in neurons and elude the surveillance of  the 
immune system, or that the immune response is not effectively activated in the 
impaired41.
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As regards peripheral nerve dissemination, coronaviruses are known to invade 
peripheral nerve terminals and spread retrogradely across nerve synapses, reach-
ing the CNS. Several viruses may spread to the peripheral nerves by binding to 
. Once the neu-
rons are infected, the viruses reside in endosomal vesicles, resulting from the 
cytomembrane during viral entry, and use dinein to transport the vesicles along 
the microtubule to the centrosome beside the nucleus. Gradually, the viral capsid 
disassembles, according to the change in pH in the endosomal vesicle, and the 
viral nucleic acids are then released to the cytoplasm, allowing viral replication. 
Finally, viral nucleic acids and viral proteins are transported to synaptic membrane 
7.
intranasal injection using a new humanized ACE knock-in-mouse model . The 
most likely way of  entering the CNS following intranasal infection is through the 
olfactory receptor neurons, also known as olfactory sensory neurons27,29.
Figure 1.3: Possible SARS-CoV-2 entry to the central nervous system (CNS)  
via the olfactory nerve
-
cells. Horizontal basal cells can mature in infected olfactory neurons that are con-
nected with neurons in the olfactory bulb; these neurons allow the viral spread 
to other areas in the CNS. Furthermore, the infected olfactory epithelial cells can 
25 with permission.
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The virus can pass the neuroepithelium of  the olfactory mucosa and reach 
the olfactory bulb, the olfactory nerve, and, from there, eventually spread to 
the hippocampus or other brain structures27,32. The ability to enter the olfactory 
models of  human coronavirus infection , and several studies have recently pro-
. Figure 1.3 shows 
olfactory receptor neurons25 -
piratory tracts, the olfactory nerve may serve as a major retrograde route for 
the spread of  the virus to the CNS -
form plate to the infected nasal epithelium, possible traumas due to sneezing, 
-
different means of  entry into the CNS through this route25,32.
-
tory epithelium
anosmia and eventually allows access of  the virus to the CNS.
The possible entry through olfactory receptor neurons has also been hy-
-
cosa of  most of  the autopsies that have been carried out41. In animal models, 
tertiary brain regions connected with the olfactory bulb, and the possibility of  
invasion of  the brain in a retrograde manner along gustatory and trigeminal 
pathways at the early stage of  infection was shown24.
Other potential routes of  brain infection through nerve dissemination could 
be possible, as well as via vagus, trigeminal and nasopharyngeal nerves; in 
25,53. 
sensory nerve endings of  the trigeminal nerve are found. In addition, local 
peripheral nerves of  the gastrointestinal tract may play a role in the retrograde 
53.
However, additional data on humans are needed to understand if  these 
mechanisms are likely to produce CNS infection25.
111. SARS-CoV-2 and the nervous system
Indirect CNS damage in the course of  SARS-CoV-2 in-
-
percoagulability and critical illness with multiorgan failure25,32,74,75.
systemic circulation, caused by a maladaptive innate immunity, may increase 
the CNS, together with infected immune cells, could damage the brain . 
 are all upregulated in the brain of  infected 
animal models and are produced in the human CNS following brain injuries37. 
implicated in cases of  an altered state of  consciousness37. Increased levels of  
.
Metabolic imbalances, including disorders of  blood calcium, sodium and glu-
cose, and renal and/or liver dysfunction, may have secondary negative effects 
on CSN function .
Systemic factors could also be responsible for the increased risk of  cerebro-
receptor on endothelial cells may result in increased blood pressure. Arterial 
hypertension can also complicate severe or critical COVID-19 as consequence 
of  the viral infection or kidney damage, and can result in ischemic or cere-
bral bleeding74. Together with an increase in blood pressure, thrombocytopenia 
and thrombus formation due to hypercoagulability in the brain or in peripheral 
and hypercoagulability that characterize severely affected patients are associat-
ed with increased risk of  thrombotic events and stroke. Cases of  myocarditis 
-
ic stroke through heart failure, with a reduction in the cerebral blood supply, 
or supra- and ventricular arrhythmias causing intra-ventricular thrombus for-
from autopsies of  COVID-19 patients .
Severe COVID-19 with acute respiratory failure, severe acute respiratory dis-
32,74 . There is, however, 
cerebral imaging: (i) the localization of  lesions in grey matter; (ii) the edema, loss 
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of  grey/white matter differentiation, reversal sign, white cerebellum sign, linear 
of  the lesions, subsequent pseudo-normalization of  the lesions after 1 week 
and T1-hyperintensity after 1-2 weeks suggesting cortical laminar necrosis on 
. The evolution of  these lesions has not been described in COVID-19 
patients. Moreover, most patients are intubated and on mechanical ventilation 
74.
established. The possible relationships between gut and brain could be due to 
a direct viral invasion of  the CNS through systemic circulation or the vagal 
nerve after entry from the gut, or the disruption of  the homeostasis of  mucosal 
immunity and gut microbiota with repercussions on the CNS. In fact, a gut 
dysbiosis induced by the virus could make the CNS even more susceptible to 
77.
One last mechanism of  possible CNS damage is the effect of  empiric treat-
ments for COVID-19; rhabdomyolisis was sometimes described after treatment 
can be caused by chloroquine or some antibiotics74. Finally, a myasthenic syn-
drome was reported after treatment with chloroquine. However, we must con-
sider that most of  these therapies are no longer recommended in the guidelines 
of  the neurological complications associated with COVID-1978,79. A possible 
alteration of  the adaptive cellular immune response to viruses could be caused 
-
sponse seems to be more important than any possible negative effects .
Indirect CNS damage during SARS-CoV-2 infection: pa-
ra-infectious and post-infectious immune-mediated disease
-
47. Autoimmune 
responses to the virus have also been proposed as para- or post-infectious 
-
tions, such as Guillain-Barré syndrome, acute necrotizing encephalopathy, and 
acute disseminated encephalomyelitis, that have been described in COVID-19 
patients .
-
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CNS tissue, causing increased viral replication or over-reactive innate immune 
responses
production of  cytokines/chemokines that ultimately damage neurons .
and a state of  cell proliferative arrest, as an adaptive response to the viral infec-
tion, eventually resulting in neurodegenerative processes. The possibility that 
neurodegenerative diseases could follow the viral infection in certain patients 
as long-term consequences is still under investigation32,58. The possible causes 
. Following latent viral infection, vascu-
processes have been well described as determinants of  neurodegeneration .
Immune-mediated demyelinating diseases have been described for other 
-
al cells; the same mechanism could lead do demyelinating diseases also after 
.
Brain regions affected by SARS-CoV-2 infection
-
tion in the CNS; one hypothesis is that the infection of  respiratory centers in 
the medulla oblongata and the pons could contribute partially to the respiratory 
breakdown of  COVID-19 patients. The spread via synapse-connected route 
into the brainstem cardiorespiratory centers of  the medulla oblongata has been 
8. 
Grey matter could be directly impacted by the infection as demonstrated by 
edema and partial neuronal degeneration observed in autopsies. Finally, demy-




degrees of  astrogliosis in all brain regions; (v) myelin loss; (vi) acute/subacute 
brain infarcts; and (vii) primary hemorrhage and microthrombi48,81,82.
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Conclusions
infection are still unknown and are likely to be multifactorial. It is likely that 
the virus could harm the CNS both directly, entering the CNS and triggering a 
and immune-mediated processes. Viral entry to the CNS is under investigation: 
through the systemic circulation crossing the BBB, through the infection of  
-
nism) or through a neuronal retrograde dissemination, via olfactory mucosa or 
gastrointestinal tract. Future studies will promote a better understanding of  the 
Take-home message
 –
causing neurological symptoms at the time of  the diagnosis or neurolog-
 –
the CNS or indirectly by para/post-infectious immune-mediated disease 
or by a secondary involvement of  the CNS in the course of  systemic 
COVID-19 disease. 
 – The virus reaches the CNS through the blood circulation crossing the 
Blood Brain Barrier (BBB) and/or through the olfactory nerve. The 
understood. 
 –
cytokines and chemokines increase the permeability of  the BBB, allow-
ing the arrival of  new viral particles, as well as immune system cells and 
 – -
ty of  establishing a latent viral reservoir in the CNS or developing neu-
rodegenerative diseases following the acute viral infection is still under 
investigation.
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